Litcius/Paper detail

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

Sumanta K. Pal, Bernard Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, Daniel Powers, David F. McDermott, Brian I. Rini

2020European Urology26 citationsDOI

Topics & Concepts

SorafenibMedicineTolerabilityRenal cell carcinomaInternal medicineOncologyHazard ratioClinical endpointTargeted therapyKidney cancerUrologyCancerConfidence intervalClinical trialAdverse effectHepatocellular carcinomaRenal cell carcinoma treatmentRenal and related cancersCancer Genomics and Diagnostics
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma | Litcius